Lupin has signed a licence and supply agreement with SteinCares to commercialise its biosimilar ranibizumab in Latin American ...

Starjemza (ustekinumab-hmny) was approved by the FDA this week as a biosimilar to Stelara. 2 A pair of clinical trials ...

Thwarted in her ambition to become a brewmaster, Kiran Mazumdar-Shaw channeled her frustrations into building a knockoff drug ...

Sanofi faces setbacks after itepekimab’s Phase 3 COPD failure, removing a key growth prospect and highlighting reliance on ...

Alvotech (ALVO) stock is in focus as the company partners with Advanz Pharma to market three additional biosimilars across ...

The Food and Drug Administration (FDA) has approved Starjemza ® (ustekinumab-hmny), a biosimilar to Stelara ® (ustekinumab), for the treatment of various chronic inflammatory diseases. Starjemza, ...

Lupin has signed a license and supply agreement with SteinCares to commercialise its biosimilar Ranibizumab across Latin ...

StainCares added that partnership plans to enhance its biosimilar portfolio and back cost-effective healthcare in Latin ...

Samsung Biologics, a biotech arm of South Korea's Samsung Group, said on Thursday it plans to spin off its biosimilar ...

Lupin Limited partners with SteinCares to license and supply ranibizumab in Latin America, excluding Mexico and Argentina.

Lupin partners with SteinCares to commercialize Ranibizumab in Latin America, aiming to improve retinal care access.

Lupin has entered into a licence agreement with SteinCares for commercialisation of biosimilar ranibizumab across Latin ...